Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2022-02-08 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is explicitly marked as a '정정신고' (Amendment Report). It details changes to previously reported stock option grants, including adjustments to the number of shares and the list of recipients. This type of disclosure regarding stock options and capital-related changes falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by financial authorities.
2022-02-08 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the procedural steps required for the meeting. Given the nature of the announcement as a regulatory disclosure of corporate action, it fits best under the RNS category.
2021-12-15 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the change in share ownership by Korea Investment Partners in SCM Lifescience. This falls under the category of Major Shareholding Notification (MRQ) as it tracks changes in significant ownership levels.
2021-12-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and their special relations. This corresponds to the 'Major Shareholding Notification' category.
2021-11-19 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from SCM Lifescience Co., Ltd. titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and includes a '정정신고' (Correction Report) section. This document details the granting of stock options to employees, which is a corporate action related to capital structure and equity compensation. In the context of Korean regulatory filings (DART system), this is classified as a report on stock option grants, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2021-11-18 Korean
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for SCM Lifescience Inc. for the period ending September 30, 2021. It contains detailed company information, history, capital changes, and governance details, which are characteristic of a comprehensive interim financial report. It is not an announcement or a certification, but the full report itself. 9M 2021
2021-11-15 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.